BAYER AG
๐ฉ๐ชGermany
- Country
- ๐ฉ๐ชGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 174
- Registration Number
- NCT02490774
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1b (Betaferon, BAY86-5046)Device: Betaconnect Autoinjector
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 162
- Registration Number
- NCT02486640
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BAY94-9343
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT02485119
- Locations
- ๐ฏ๐ต
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
๐ฏ๐ตNational Cancer Center Hospital, Tyuo, Japan
Real-Life Evidence on Stroke Prevention in SPAF
Completed
- Conditions
- Atrial Fibrillation (Prevention of Stroke)
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8607
- Registration Number
- NCT02485873
Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT02483208
Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea
Completed
- Conditions
- Menorrhagia, Dysmenorrhea
- Interventions
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 601
- Registration Number
- NCT02475356
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
Completed
- Conditions
- StrokeAtrial FibrillationPrevention and Control
- Interventions
- Drug: Direct Oral Anticoagulant (DOAC)
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 792
- Registration Number
- NCT02470767
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
Completed
- Conditions
- Venous ThrombosisAcute Coronary SyndromePulmonary EmbolismAtrial Fibrillation
- Interventions
- Drug: Standard of care drugs
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT02468102
- Locations
- ๐ธ๐ช
Many Locations, Multiple Locations, Sweden
Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids
Phase 2
Completed
- Conditions
- Leiomyoma
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 120
- Registration Number
- NCT02465814
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 59
- Registration Number
- NCT02465502
ยฉ Copyright 2025. All Rights Reserved by MedPath